Showing 1,581 - 1,600 results of 2,974 for search '"drug interaction"', query time: 0.20s Refine Results
  1. 1581

    Antifungal Siderophore Conjugates for Theranostic Applications in Invasive Pulmonary Aspergillosis Using Low-Molecular TAFC Scaffolds by Joachim Pfister, Milos Petrik, Katerina Bendova, Barbara Matuszczak, Ulrike Binder, Matthias Misslinger, Alexander Kühbacher, Fabio Gsaller, Hubertus Haas, Clemens Decristoforo

    Published 2021-07-01
    “…Diagnostic procedures are often invasive and/or time consuming and existing antifungals can be constrained by dose-limiting toxicity and drug interaction. In this study, we modified triacetylfusarinine C (TAFC), the main siderophore produced by the opportunistic pathogen <i>Aspergillus fumigatus</i> (<i>A. fumigatus</i>), with antifungal molecules to perform antifungal susceptibility tests and molecular imaging. …”
    Get full text
    Article
  2. 1582

    Development of evidence-based indicators for the detection of drug-related problems among ovarian cancer patients by Kala Bahadur Rawal, Uday Venkat Mateti, Vijith Shetty, Chakrakodi Shashidhara Shastry, Mazhuvancherry Kesavan Unnikrishnan, Shraddha Shetty, Aparna Rajesh

    Published 2023-06-01
    “…A total of 803 pDRPs were identified under four main categories: drug selection problem, drug use problem, adverse drug reaction and drug-drug interaction The most frequently observed were ADR 381 (47.45%), DDIs 354 (44.08%), and drug selection problems 62 (7.72%).Conclusion: Indicators developed by us effectively identified pDRPs in ovarian cancer patients, which can potentially help healthcare professionals in the early detection, timely management, and attenuating severity of DRPs. …”
    Get full text
    Article
  3. 1583

    Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains by Rodrigo Rollin-Pinheiro, Brayan Bayona-Pacheco, Levy Tenorio Sousa Domingos, Jose Alexandre da Rocha Curvelo, Gabriellen Menezes Migliani de Castro, Eliana Barreto-Bergter, Antonio Ferreira-Pereira

    Published 2021-07-01
    “…Regarding the evaluation of drug interaction, both aureobasidin A and myriocin were synergic with fluconazole, demonstrating that sphingolipid synthesis inhibition could enhance the effect of fluconazole. …”
    Get full text
    Article
  4. 1584

    Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network by Denise Feick, Simeon Rüdesheim, Fatima Zahra Marok, Dominik Selzer, Helena Leonie Hanae Loer, Donato Teutonico, Sebastian Frechen, Maaike van derLee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr

    Published 2023-08-01
    “…Abstract The antiarrhythmic agent quinidine is a potent inhibitor of cytochrome P450 (CYP) 2D6 and P‐glycoprotein (P‐gp) and is therefore recommended for use in clinical drug–drug interaction (DDI) studies. However, as quinidine is also a substrate of CYP3A4 and P‐gp, it is susceptible to DDIs involving these proteins. …”
    Get full text
    Article
  5. 1585

    Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysi... by Amal Qattan, Taher Al-Tweigeri, Wafa Alkhayal, Kausar Suleman, Asma Tulbah, Suad Amer

    Published 2021-04-01
    “…MiRNA expression analysis was used to investigate differentially regulated circulating miRNAs in TNBC patients, and integrated pathway regulation, gene ontology, and pharmacogenomic network analyses were used to identify target genes, miRNAs, and drug interaction networks. Herein, we identified significant differentially expressed circulating miRNAs in TNBC patients (miR-19a/b-3p, miR-25-3p, miR-22-3p, miR-210-3p, miR-93-5p, and miR-199a-3p) that regulate several molecular pathways (PAM (PI3K/Akt/mTOR), HIF-1, TNF, FoxO, Wnt, and JAK/STAT, PD-1/PD-L1 pathways and EGFR tyrosine kinase inhibitor resistance (TKIs)) involved in drug resistance. …”
    Get full text
    Article
  6. 1586

    Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital... by Tegegne BA, Alehegn AA, Kassahun M

    Published 2024-04-01
    “…Five criteria, namely, indication, dose, contraindication, drug interaction, and TLD safety monitoring were used to evaluate the appropriateness of TLD utilization.Results: 80% of patients were transited to TLD from other regimens. …”
    Get full text
    Article
  7. 1587

    Cyclic and Acyclic Amine Oxide Alkyl Derivatives as Potential Adjuvants in Antimicrobial Chemotherapy against Methicillin-Resistant <i>Staphylococcus aureus</i> with an MDR Profile by Lorenza Fagnani, Lisaurora Nazzicone, Fabrizia Brisdelli, Luisa Giansanti, Sara Battista, Roberto Iorio, Sabrina Petricca, Gianfranco Amicosante, Mariagrazia Perilli, Giuseppe Celenza, Pierangelo Bellio

    Published 2021-08-01
    “…The compounds show an efficacious antimicrobial activity strongly related to the length of the carbon atom chain. In drug–drug interaction assays, all surfactants act synergistically, restoring sensitivity to oxacillin in MRSA, with dodecyl acyclic and cyclic derivatives being the most effective. …”
    Get full text
    Article
  8. 1588

    The influence of green tea extract on nintedanib’s bioavailability in patients with pulmonary fibrosis by G.D.Marijn Veerman, Sanne C. van der Werff, Stijn L.W. Koolen, Jelle R. Miedema, Esther Oomen-de Hoop, Sophie C. van der Mark, Prewesh P. Chandoesing, Peter de Bruijn, Marlies S. Wijsenbeek, Ron H.J. Mathijssen

    Published 2022-07-01
    “…We investigated if concomitant administration of green tea extract (GTE) could result in a clinically relevant herb-drug interaction.Patients were randomized between A-B and B-A, with A being nintedanib alone and B nintedanib with GTE. …”
    Get full text
    Article
  9. 1589

    Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD) by Shi-Tao Jiang, Yao-Ge Liu, Lei Zhang, Xin-Ting Sang, Yi-Yao Xu, Xin Lu

    Published 2022-11-01
    “…In addition, we also constructed TFs–DEGs, miRNAs–DEGs, and protein–drug interaction networks, demonstrating the complex regulatory relationships of common DEGs. …”
    Get full text
    Article
  10. 1590

    Pyrazoline B-Paclitaxel or Doxorubicin Combination Drugs Show Synergistic Activity Against Cancer Cells: In silico Study by Wiraswati HL, Bashari MH, Alfarafisa NM, Ma'ruf IF, Sholikhah EN, Wahyuningsih TD, Satriyo PB, Mustofa M, Satria D, Damayanti E

    Published 2024-02-01
    “…To increase the efficacy of this drug, co-administration with established anticancer drugs such as doxorubicin and paclitaxel is necessary.Materials and Methods: In this study, we used an in silico approach to predict the synergistic effect of pyrazoline B with paclitaxel or doxorubicin using various computational frameworks and compared the results with those of an established study on the combination of doxorubicin-cyclophosphamide and paclitaxel-ascorbic acid.Results and Discussion: Drug interaction analysis showed the combination was safe with no contraindications or side effects. …”
    Get full text
    Article
  11. 1591
  12. 1592

    Simultaneous absolute protein quantification of seven cytochrome P450 isoforms in rat liver microsomes by LC-MS/MS-based isotope internal standard method by Fulin Jiang, Chang Zhang, Zihan Lu, Jingyu Liu, Peiqing Liu, Min Huang, Guoping Zhong

    Published 2022-08-01
    “…LC-MS/MS-based targeting technology has been applied to the analysis of CYP enzymes, promoting drug development and drug-drug interaction studies. Rat is one of the most commonly used models for drug metabolism assessment, but LC-MS/MS assay quantifying the abundance of CYP enzymes in rats is rarely reported. …”
    Get full text
    Article
  13. 1593

    Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective colon cancer therapy by Yosif Almoshari, Haroon Iqbal, Anam Razzaq, Khalil Ali Ahmad, Muhammad Khalid Khan, Saad Saeed Alqahtani, Muhammad H. Sultan, Barkat Ali Khan

    Published 2022-12-01
    “…We also physiochemically characterized the nanocubosomes by transmission electron microscopy (TEM), Fourier transform infrared (FTIR), and x-rays diffraction (XRD) for their morphology, polymer drug interaction and its nature, respectively. Further, the in-vitro cell-uptake, mechanism of cell-uptake, in-vitro anti-tumor efficacy and apoptosis level were evaluated using HCT-116 colon cancer cells. …”
    Get full text
    Article
  14. 1594

    Pharmacokinetic Variability of Oral Cannabidiol and Its Major Metabolites after Short-Term High-Dose Exposure in Healthy Subjects by Qingchen Zhang, Philip W. Melchert, John S. Markowitz

    Published 2024-01-01
    “…Methods: Blood samples from a previously conducted CBD drug interaction study in healthy volunteers (n = 12) were utilized. …”
    Get full text
    Article
  15. 1595

    Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity by Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård

    Published 2023-12-01
    “…Two other trials also contributed to the findings reported in this article: a first human dose (FHD)/single ascending dose (SAD), placebo-controlled, double-blind trial in which adults (N = 49) received NN1177 (treatment doses of 10, 40, 120, 350, 700 and 1100 μg) or placebo, and a drug–drug interaction, open-label, single-sequence trial in which adults (N = 45) received a 4200-μg dose of NN1177, following administration of a Cooperstown 5 + 1 index cocktail. …”
    Get full text
    Article
  16. 1596

    Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells by Diana Duarte, Alexandra Rêma, Irina Amorim, Nuno Vale

    Published 2022-01-01
    “…Studies were also complemented with morphological evaluation. Assessment of drug interaction was performed using the CompuSyn and SynergyFinder software. …”
    Get full text
    Article
  17. 1597

    Facts and myths about the use of lithium for bipolar disorder in routine clinical practice: an expert consensus paper by Andrea Fiorillo, Gaia Sampogna, Umberto Albert, Giuseppe Maina, Giulio Perugi, Maurizio Pompili, Gianluca Rosso, Gabriele Sani, Alfonso Tortorella

    Published 2023-12-01
    “…The most common false myths have been critically revised and the following statements have been proposed: (1) Lithium should represent the first choice for the treatment of patients with bipolar disorder; (2) lithium treatment is effective in different patients’ groups suffering from bipolar disorder; (3) Drug–drug interaction risk can be easily managed during lithium treatment; (4) The optimal management of lithium treatment includes periodical laboratory tests; (5) Slow-release lithium formulation has advantages compared to immediate release formulation; (6) Lithium treatment has antisuicidal properties; (7) Lithium can be carefully managed during pregnancy. …”
    Get full text
    Article
  18. 1598

    Study of the ketohexokinase inhibitor PF‐06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy by Ruolun Qiu, Kari Fonseca, Arthur Bergman, Jian Lin, David Tess, Lauren Newman, Alia Fahmy, Zivile Useckaite, Andrew Rowland, Manoli Vourvahis, David Rodrigues

    Published 2024-01-01
    “…Therefore, a drug–drug interaction study was conducted to evaluate the effect of multiple doses of PF‐06835919 (300 mg once daily × 10 days; N = 10 healthy participants) on the pharmacokinetics of a single oral midazolam 7.5 mg dose. …”
    Get full text
    Article
  19. 1599

    Caracterização do uso de medicamentos entre idosos de uma unidade do Programa Saúde da Família Use of medicines by the elderly in a Family Health Program unit in Brazil by Maria José Sanches Marin, Luiz Carlos de Oliveira Cecílio, Alexandre Eduardo W. Ugolini Ferrazoli Perez, Fernando Santella, Camila Batista Andrade Silva, José Roberto Gonçalves Filho, Lidiane Cola Roceti

    Published 2008-07-01
    “…Although such practice is usually necessary, it predisposes to risks of adverse events and drug interaction. The present study was intended to verify the characteristics of medication among the elderly in relation to socio-demographic profile, the most commonly used drug classes, and treatment adherence. …”
    Get full text
    Article
  20. 1600

    Drug-related problems in hospitalized patients with type 2 diabetes mellitus: A systematic review by Mohammad Hisyamuddin Awang Jihadi, Ana Yuda, Anila Impian Sukorini, Andi Hermansyah, Naeem Shafqat, Ching Siang Tan, Long Chiau Ming

    Published 2023-12-01
    “…The most common DRPs included drug-drug interaction (DDI), adverse drug reaction (ADR), therapeutic effectiveness problems, and inappropriate medication use. …”
    Get full text
    Article